This combination therapy of RT and PD-1/PD-L1 inhibitor improved the long-term survival in preclinical studies and mouse models of melanoma, colorectal cancer, breast cancer, and NSCLC [175–177], while also preventing tumor recurrence. This evidence concerns the gene CD274 and non-small cell lung carcinoma.